Grifols, S.A. (NASDAQ:GRFS - Get Free Report)'s stock price gapped up before the market opened on Monday . The stock had previously closed at $7.06, but opened at $7.21. Grifols shares last traded at $7.18, with a volume of 69,628 shares.
Grifols Trading Up 1.4 %
The company has a current ratio of 1.68, a quick ratio of 1.29 and a debt-to-equity ratio of 1.06. The firm has a market cap of $4.92 billion, a PE ratio of 7.08 and a beta of 0.49. The business has a fifty day moving average price of $7.38 and a 200 day moving average price of $7.25.
Grifols (NASDAQ:GRFS - Get Free Report) last announced its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.21). Grifols had a net margin of 0.90% and a return on equity of 1.73%. The company had revenue of $1.96 billion during the quarter. Analysts forecast that Grifols, S.A. will post 0.79 EPS for the current year.
Institutional Investors Weigh In On Grifols
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Capital World Investors boosted its stake in shares of Grifols by 4.9% during the first quarter. Capital World Investors now owns 20,749,225 shares of the biotechnology company's stock worth $138,605,000 after buying an additional 961,700 shares during the period. Brandes Investment Partners LP raised its stake in shares of Grifols by 8.7% during the second quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company's stock worth $117,242,000 after purchasing an additional 1,481,924 shares during the last quarter. Black Creek Investment Management Inc. lifted its holdings in shares of Grifols by 7.7% during the second quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company's stock worth $77,799,000 after purchasing an additional 881,155 shares during the period. Armistice Capital LLC grew its position in Grifols by 18.7% in the 2nd quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company's stock valued at $49,759,000 after buying an additional 1,244,000 shares during the last quarter. Finally, First Trust Advisors LP increased its stake in Grifols by 6.9% in the 4th quarter. First Trust Advisors LP now owns 4,684,749 shares of the biotechnology company's stock valued at $54,156,000 after buying an additional 302,380 shares during the period.
Grifols Company Profile
(Get Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Recommended Stories
- Five stocks we like better than Grifols
- What is a buyback in stocks? A comprehensive guide for investors
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- The 3 Best Retail Stocks to Shop for in August
- 2 Option Strategies to Maximize Profits in a Bear Market
- Lululemon Stock Gears Up for a Massive Comeback Rally
→ President Reagan's Final Warning (From Behind the Markets) (Ad)
Should you invest $1,000 in Grifols right now?
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
20 Stocks to Sell Now
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
